Table 2.

Pre- and post-treatment histopathology results: randomized, placebo-controlled trial of lycopene supplement in men with HGPIN

	Lycopene (n = 26)			Placebo (n = 32)
	Pre-Rx	Post-Rx	P *	Pre-Rx	Post-Rx	P
Prostate cancer, n (%)	0	4 (15)	0.11	0	4 (13)	0.11
HGPIN, n (%)
Present, any no. cores	26 (100)	11 (42)	< 0.01	32 (100)	18 (56)	< 0.01
1 core positive	16 (62)	7 (27)	0.03	21 (66)	11 (34)	0.02
≥ 2 cores positive	10 (38)	4 (16)	0.12	11 (34)	7 (22)	0.40
Mean no. HGPIN cores	1.73	0.65	<0.001	1.41	0.88	0.005
Proliferative inflammatory atrophy, n (%)	6 (23)	5 (19)	0.99	10 (31)	11 (34)	0.99
Focal atrophy, n (%)
Present, any no. cores	16 (62)	17 (65)	0.99	22 (69)	20 (63)	0.79
1-2 cores	7 (27)	6 (23)	0.99	10 (31)	8 (25)	0.78
3-4 cores	8 (31)	4 (15)	0.32	6 (19)	4 (13)	0.73
≥ 5 cores	1 (4)	7 (27)	0.05	6 (19)	8 (25)	0.77
Mean no. cores	1.73	2.81	0.05	2.66	2.34	0.58
Inflammation, n (%)
Present, any no. cores	20 (77)	16 (62)	0.37	18 (56)	21 (66)	0.61
1-2 cores	13 (50)	8 (31)	0.26	13 (41)	13 (41)	0.99
3-4 cores	6 (23)	6 (23)	0.99	3 (9)	6 (19)	0.47
≥ 5 cores	1 (4)	2 (8)	0.99	2 (6)	2 (6)	0.99
Mean no. cores	1.65	1.73	0.88	1.25	1.66	0.30

^*P values are Fisher exact (2-tailed) for comparison of proportions and paired T test (2-tailed) for comparison of means.